 BOSTON, Nov. 10, 2022 GLOBE NEWSWIRE -- HilleVax, Inc. Nasdaq: HLVX, a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will participate in the Guggenheim Securities 4th Annual Immunology and Neurology Day and the Stifel Healthcare Conference. HIL-214, HilleVaxs investigational virus-like particle VLP based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the related ongoing Phase 2b clinical trial NEST-IN1 will be topics of discussion at both events. 